BRAF and thyroid gland disorder: Indeed, the oncogenic activation of BRAF leads to constitutive activation of downstream signaling through MAPK pathway [3] and favors the development of biologically and clinically aggressive thyroid and colorectal malignancies, frequently resistant to conventional anticancer therapies [4, 5].